Communiqués HUTCHMED (China) Limited Nasdaq

Actions

HCM

US44842L1035

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 14/06/2024			Varia. 5j.	Varia. 1 janv.
18,12 ^USD	-2,79%		+2,03%	+0,06%

11:35	Hutchmed annonce des résultats "prometteurs" pour le sovleplenib en Chine	AN
10/06	Transcript : HUTCHMED Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology	02:00	AQ
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be presented at the upcoming EHA2024 Congress	20/05	AQ
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda	29/04	AQ
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status	03/04	AQ
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China	22/03	AQ
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session	07/02	AQ
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership	02/02	AQ
HUTCHMED to Announce 2023 Final Results	01/02	AQ
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20/12	AQ
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms	13/12	AQ
HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China	13/12	AQ
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses	01/12	AQ
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023	16/10/23	AQ
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan	29/09/23	AQ
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer	12/09/23	AQ
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer	29/08/23	AQ
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China	21/08/23	AQ
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study	20/07/23	AQ
HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China	10/07/23	AQ
HUTCHMED to Announce 2023 Half-Year Financial Results	26/06/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués HUTCHMED (China) Limited Nasdaq

Actions

HCM

US44842L1035

Communiqués

Filtres